Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Autism spectrum disorder (ASD) is a very heterogeneous disorder with limited empirically validated behavioral and biological interventions. The goal of this pilot investigation is to apply a biologically-based approach to identify predictors of treatment response in children with ASD who are receiving Pivotal Response Treatment (PRT), an evidence-based behavioral intervention. Specifically, the investigators propose to identify neuroimaging biomarkers of treatment response to a PRT program (PRT-P) targeting language deficits in young children with ASD who will be randomized to either PRT-P or to a delayed treatment group (DTG).

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of Autism Spectrum Spectrum Disorder (ASD) based on clinical interview and Diagnostic and Statistical Manual, 5th edition (DSM-5) and confirmed using the Autism Diagnostic Interview Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) and/or Brief Observation of Symptoms of Autism (BOSA) and/or Childhood Autism Rating Scale- Second Edition (CARS-2). - Outpatients between 2.0 and 4.11 years of age of either gender, - Children of all cognitive levels will be included as long as they are able to participate in the testing procedures to the extent that valid standard scores can be obtained - Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5) \[at least 1 standard deviation behind for children age 2 and 3 years; and 2 standard deviations behind for children age 4\], - Stable psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation, - Stable treatment \[Applied Behavior Analysis (ABA), Floortime, or other interventions\], speech therapy, and school placement for at least 1 month prior to baseline measurements with no expected changes during study participation, - No more than 60 minutes of 1:1 speech therapy per week, - The child's exposure to the English language must be sufficient that administration of standardized tests in English is appropriate for measuring progress, - The availability of at least one parent who can consistently participate in the training sessions and related activities, and - Successful completion of baseline brain scan. Who Should NOT Join This Trial: - Current or life-time diagnosis of severe psychiatric disorder (e.g., bipolar disorder), - Genetic abnormality (e.g., Fragile X) - Presence of active medical problem (e.g., unstable seizure disorder), - Receiving more than 15 hours of in home 1:1 Applied Behavior Analysis (ABA) per week ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diagnosis of Autism Spectrum Spectrum Disorder (ASD) based on clinical interview and Diagnostic and Statistical Manual, 5th edition (DSM-5) and confirmed using the Autism Diagnostic Interview Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) and/or Brief Observation of Symptoms of Autism (BOSA) and/or Childhood Autism Rating Scale- Second Edition (CARS-2). * Outpatients between 2.0 and 4.11 years of age of either gender, * Children of all cognitive levels will be included as long as they are able to participate in the testing procedures to the extent that valid standard scores can be obtained * Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5) \[at least 1 standard deviation behind for children age 2 and 3 years; and 2 standard deviations behind for children age 4\], * Stable psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation, * Stable treatment \[Applied Behavior Analysis (ABA), Floortime, or other interventions\], speech therapy, and school placement for at least 1 month prior to baseline measurements with no expected changes during study participation, * No more than 60 minutes of 1:1 speech therapy per week, * The child's exposure to the English language must be sufficient that administration of standardized tests in English is appropriate for measuring progress, * The availability of at least one parent who can consistently participate in the training sessions and related activities, and * Successful completion of baseline brain scan. Exclusion Criteria: * Current or life-time diagnosis of severe psychiatric disorder (e.g., bipolar disorder), * Genetic abnormality (e.g., Fragile X) * Presence of active medical problem (e.g., unstable seizure disorder), * Receiving more than 15 hours of in home 1:1 Applied Behavior Analysis (ABA) per week * Magnetic Resonance (MR) contraindication (e.g., the presence of ferrous metal), or * Previous adequate Pivotal Response Treatment (PRT) trial.

Treatments Being Tested

BEHAVIORAL

Pivotal Response Treatment Program (PRT-P)

The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.

Locations (1)

Stanford University
Stanford, California, United States